85% enrolled with anticipated completion in Q2 2026 with BLA filing to U.S. Food and Drug Administration (FDA) by year end Interim analysis requested by FDA demonstrated statistically significant ...
Enrollment of BCG naïve subjects (QUILT-2.005) receiving BCG alone versus BCG plus ANKTIVA exceeding expectations 85% enrolled with anticipated completion in Q2 2026 with BLA filing to U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results